389 related articles for article (PubMed ID: 19370189)
1. [Evidences of safety and tolerability of the zoledronic acid 5 mg yearly in the post-menopausal osteoporosis: the HORIZON project].
Dalle Carbonare L; Bertoldo F; Lo Cascio V
Reumatismo; 2009; 61(1):54-64. PubMed ID: 19370189
[TBL] [Abstract][Full Text] [Related]
2. Effects of intravenous zoledronic acid once yearly on bone remodeling and bone structure.
Recker RR; Delmas PD; Halse J; Reid IR; Boonen S; García-Hernandez PA; Supronik J; Lewiecki EM; Ochoa L; Miller P; Hu H; Mesenbrink P; Hartl F; Gasser J; Eriksen EF
J Bone Miner Res; 2008 Jan; 23(1):6-16. PubMed ID: 17892374
[TBL] [Abstract][Full Text] [Related]
3. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis.
Black DM; Delmas PD; Eastell R; Reid IR; Boonen S; Cauley JA; Cosman F; Lakatos P; Leung PC; Man Z; Mautalen C; Mesenbrink P; Hu H; Caminis J; Tong K; Rosario-Jansen T; Krasnow J; Hue TF; Sellmeyer D; Eriksen EF; Cummings SR;
N Engl J Med; 2007 May; 356(18):1809-22. PubMed ID: 17476007
[TBL] [Abstract][Full Text] [Related]
4. Once-yearly administered intravenous zoledronic acid for postmenopausal osteoporosis.
Woodis CB
Ann Pharmacother; 2008 Jul; 42(7):1085-9. PubMed ID: 18505912
[TBL] [Abstract][Full Text] [Related]
5. Intravenous Zoledronic Acid 5 mg on Bone Turnover Markers and Bone Mineral Density in East China Subjects with Newly Diagnosed Osteoporosis: A 24-month Clinical Study.
Liang BC; Shi ZY; Wang B; Wu P; Kong LC; Yao JL; Li CW; Shi XL
Orthop Surg; 2017 Feb; 9(1):103-109. PubMed ID: 28276638
[TBL] [Abstract][Full Text] [Related]
6. [Fracture prevention in postmenopausal women with osteoporosis by an annual infusion of zoledronic acid].
Geusens PP; Lems WF
Ned Tijdschr Geneeskd; 2007 Jun; 151(26):1445-8. PubMed ID: 17633971
[TBL] [Abstract][Full Text] [Related]
7. Intravenous bisphosphonates for postmenopausal osteoporosis: safety profiles of zoledronic acid and ibandronate in clinical practice.
Sieber P; Lardelli P; Kraenzlin CA; Kraenzlin ME; Meier C
Clin Drug Investig; 2013 Feb; 33(2):117-22. PubMed ID: 23184667
[TBL] [Abstract][Full Text] [Related]
8. Review of the cardiovascular safety of zoledronic acid and other bisphosphonates for the treatment of osteoporosis.
John Camm A
Clin Ther; 2010 Mar; 32(3):426-36. PubMed ID: 20399982
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of once-yearly zoledronic acid in Japanese patients with primary osteoporosis: two-year results from a randomized placebo-controlled double-blind study (ZOledroNate treatment in Efficacy to osteoporosis; ZONE study).
Nakamura T; Fukunaga M; Nakano T; Kishimoto H; Ito M; Hagino H; Sone T; Taguchi A; Tanaka S; Ohashi M; Ota Y; Shiraki M
Osteoporos Int; 2017 Jan; 28(1):389-398. PubMed ID: 27631091
[TBL] [Abstract][Full Text] [Related]
10. Effects of intravenous zoledronic acid plus subcutaneous teriparatide [rhPTH(1-34)] in postmenopausal osteoporosis.
Cosman F; Eriksen EF; Recknor C; Miller PD; Guañabens N; Kasperk C; Papanastasiou P; Readie A; Rao H; Gasser JA; Bucci-Rechtweg C; Boonen S
J Bone Miner Res; 2011 Mar; 26(3):503-11. PubMed ID: 20814967
[TBL] [Abstract][Full Text] [Related]
11. Intravenous zoledronic acid 5 mg in the treatment of postmenopausal women with low bone density previously treated with alendronate.
McClung M; Recker R; Miller P; Fiske D; Minkoff J; Kriegman A; Zhou W; Adera M; Davis J
Bone; 2007 Jul; 41(1):122-8. PubMed ID: 17468062
[TBL] [Abstract][Full Text] [Related]
12. Annual intravenous zoledronic acid for three years increased cancellous bone matrix mineralization beyond normal values in the HORIZON biopsy cohort.
Misof BM; Roschger P; Gabriel D; Paschalis EP; Eriksen EF; Recker RR; Gasser JA; Klaushofer K
J Bone Miner Res; 2013 Mar; 28(3):442-8. PubMed ID: 23044788
[TBL] [Abstract][Full Text] [Related]
13. The effects of intravenous zoledronic acid in Chinese women with postmenopausal osteoporosis.
Hwang JS; Chin LS; Chen JF; Yang TS; Chen PQ; Tsai KS; Leung PC
J Bone Miner Metab; 2011 May; 29(3):328-33. PubMed ID: 20922438
[TBL] [Abstract][Full Text] [Related]
14. Relationship of changes in total hip bone mineral density to vertebral and nonvertebral fracture risk in women with postmenopausal osteoporosis treated with once-yearly zoledronic acid 5 mg: the HORIZON-Pivotal Fracture Trial (PFT).
Jacques RM; Boonen S; Cosman F; Reid IR; Bauer DC; Black DM; Eastell R
J Bone Miner Res; 2012 Aug; 27(8):1627-34. PubMed ID: 22532515
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of a once-yearly intravenous zoledronic acid 5 mg for fracture prevention in elderly postmenopausal women with osteoporosis aged 75 and older.
Boonen S; Black DM; Colón-Emeric CS; Eastell R; Magaziner JS; Eriksen EF; Mesenbrink P; Haentjens P; Lyles KW
J Am Geriatr Soc; 2010 Feb; 58(2):292-9. PubMed ID: 20070415
[TBL] [Abstract][Full Text] [Related]
16. Zoledronic acid: a review of its use in the treatment of osteoporosis.
Deeks ED; Perry CM
Drugs Aging; 2008; 25(11):963-86. PubMed ID: 18947264
[TBL] [Abstract][Full Text] [Related]
17. Rapid Onset and Sustained Efficacy (ROSE) study: results of a randomised, multicentre trial comparing the effect of zoledronic acid or alendronate on bone metabolism in postmenopausal women with low bone mass.
Hadji P; Gamerdinger D; Spieler W; Kann PH; Loeffler H; Articus K; Möricke R; Ziller V
Osteoporos Int; 2012 Feb; 23(2):625-33. PubMed ID: 21442459
[TBL] [Abstract][Full Text] [Related]
18. Renal safety of annual zoledronic acid infusions in osteoporotic postmenopausal women.
Boonen S; Sellmeyer DE; Lippuner K; Orlov-Morozov A; Abrams K; Mesenbrink P; Eriksen EF; Miller PD
Kidney Int; 2008 Sep; 74(5):641-8. PubMed ID: 18509324
[TBL] [Abstract][Full Text] [Related]
19. Single annual injectable treatment for postmenopausal osteoporosis.
Chapurlat RD
Expert Opin Drug Deliv; 2008 May; 5(5):583-91. PubMed ID: 18491983
[TBL] [Abstract][Full Text] [Related]
20. Intravenous zoledronic acid in postmenopausal women with low bone mineral density.
Reid IR; Brown JP; Burckhardt P; Horowitz Z; Richardson P; Trechsel U; Widmer A; Devogelaer JP; Kaufman JM; Jaeger P; Body JJ; Brandi ML; Broell J; Di Micco R; Genazzani AR; Felsenberg D; Happ J; Hooper MJ; Ittner J; Leb G; Mallmin H; Murray T; Ortolani S; Rubinacci A; Saaf M; Samsioe G; Verbruggen L; Meunier PJ
N Engl J Med; 2002 Feb; 346(9):653-61. PubMed ID: 11870242
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]